These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 22126021)

  • 1. HE4 in ovarian cancer: from discovery to clinical application.
    Montagnana M; Danese E; Giudici S; Franchi M; Guidi GC; Plebani M; Lippi G
    Adv Clin Chem; 2011; 55():1-20. PubMed ID: 22126021
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The values of serum human epididymis secretory protein 4 and CA(125) assay in the diagnosis of ovarian malignancy].
    Dong L; Chang XH; Ye X; Zhu LR; Zhao Y; Tian L; Cheng HY; Li XP; Zhang H; Liao QP; Fu TY; Cheng YX; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2008 Dec; 43(12):931-6. PubMed ID: 19134334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and application of protein biomarkers for ovarian cancer.
    Gagnon A; Ye B
    Curr Opin Obstet Gynecol; 2008 Feb; 20(1):9-13. PubMed ID: 18196999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.
    Moore RG; Brown AK; Miller MC; Skates S; Allard WJ; Verch T; Steinhoff M; Messerlian G; DiSilvestro P; Granai CO; Bast RC
    Gynecol Oncol; 2008 Feb; 108(2):402-8. PubMed ID: 18061248
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening and detection of ovarian cancer.
    Breedlove G; Busenhart C
    J Midwifery Womens Health; 2005; 50(1):51-4. PubMed ID: 15637515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Measurement of serum human epididymis secretory protein 4 combined with CA125 assay in differential diagnosis of endometriosis cyst and ovarian benign and malignant tumors].
    Liu YN; Ye X; Cheng HY; Cheng YX; Fu TY; Chen J; Chang XH; Cui H
    Zhonghua Fu Chan Ke Za Zhi; 2010 May; 45(5):363-6. PubMed ID: 20646446
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic performances of HE4 and CA125 for the detection of ovarian cancer from patients with various gynecologic and non-gynecologic diseases.
    Park Y; Lee JH; Hong DJ; Lee EY; Kim HS
    Clin Biochem; 2011 Jul; 44(10-11):884-8. PubMed ID: 21549107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A step forward for two-step screening for ovarian cancer.
    Hensley ML
    J Clin Oncol; 2010 May; 28(13):2128-30. PubMed ID: 20368556
    [No Abstract]   [Full Text] [Related]  

  • 9. New tumor markers: CA125 and beyond.
    Bast RC; Badgwell D; Lu Z; Marquez R; Rosen D; Liu J; Baggerly KA; Atkinson EN; Skates S; Zhang Z; Lokshin A; Menon U; Jacobs I; Lu K
    Int J Gynecol Cancer; 2005; 15 Suppl 3():274-81. PubMed ID: 16343244
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current clinical use of biomarkers for epithelial ovarian cancer.
    Moore RG; Maclaughlan S
    Curr Opin Oncol; 2010 Sep; 22(5):492-7. PubMed ID: 20613519
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in ovarian cancer proteomics: the quest for biomarkers and improved therapeutic interventions.
    Jurisicova A; Jurisica I; Kislinger T
    Expert Rev Proteomics; 2008 Aug; 5(4):551-60. PubMed ID: 18761466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of human epididymis protein 4 gene silencing on the malignant phenotype in ovarian cancer.
    Zou SL; Chang XH; Ye X; Cheng HY; Cheng YX; Tang ZJ; Zhang ZJ; Gao L; Chen XH; Cui H
    Chin Med J (Engl); 2011 Oct; 124(19):3133-40. PubMed ID: 22040568
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women.
    Holcomb K; Vucetic Z; Miller MC; Knapp RC
    Am J Obstet Gynecol; 2011 Oct; 205(4):358.e1-6. PubMed ID: 21722869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human epididymis protein 4 (HE4) as a serum tumor biomarker in patients with ovarian carcinoma.
    Chang X; Ye X; Dong L; Cheng H; Cheng Y; Zhu L; Liao Q; Zhao Y; Tian L; Fu T; Chen J; Cui H
    Int J Gynecol Cancer; 2011 Jul; 21(5):852-8. PubMed ID: 21633297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HE4 as an Early Detection Biomarker of Epithelial Ovarian Cancer: Investigations in Prediagnostic Specimens From the Janus Serumbank.
    Gislefoss RE; Langseth H; Bolstad N; Nustad K; Mørkrid L
    Int J Gynecol Cancer; 2015 Nov; 25(9):1608-15. PubMed ID: 26501436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HE4 in the differential diagnosis of ovarian masses.
    Granato T; Porpora MG; Longo F; Angeloni A; Manganaro L; Anastasi E
    Clin Chim Acta; 2015 Jun; 446():147-55. PubMed ID: 25892674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [HE4--a new tumor marker for ovarian cancer].
    Manolov V; Marinov B; Vasilev V; Andreeva A
    Akush Ginekol (Sofiia); 2011; 50 Suppl 2():11-5. PubMed ID: 22524132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Soluble epidermal growth factor receptor (sEGFR) [corrected] and cancer antigen 125 (CA125) as screening and diagnostic tests for epithelial ovarian cancer.
    Baron AT; Boardman CH; Lafky JM; Rademaker A; Liu D; Fishman DA; Podratz KC; Maihle NJ
    Cancer Epidemiol Biomarkers Prev; 2005 Feb; 14(2):306-18. PubMed ID: 15734951
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor markers in epithelial ovarian cancer. Clinical applications.
    Hempling RE
    Obstet Gynecol Clin North Am; 1994 Mar; 21(1):41-61. PubMed ID: 8015766
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of biomarker panels for early stage ovarian cancer detection and monitoring for disease recurrence.
    Havrilesky LJ; Whitehead CM; Rubatt JM; Cheek RL; Groelke J; He Q; Malinowski DP; Fischer TJ; Berchuck A
    Gynecol Oncol; 2008 Sep; 110(3):374-82. PubMed ID: 18584856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.